Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiraterone acetate plus prednisone and ADT versus ADT alone in newly diagnosed high-risk metastatic hormone-naive prostate cancer
NL-OMON44898Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of abiraterone and prednisone in prostate cancer (PCa) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Radiographic progression-free survival and Overall survival. Started Feb 2014; status: active, not recruiting.
02
Drugs
abirateroneprednisone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON44898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44898.